坎格雷洛是一种用于2015年6月静脉应用的抗血小板药物的PYY12抑制剂。一些P2Y12抑制剂被临床用作二磷酸腺苷介导的血小板活化和聚集的有效抑制剂。与氯吡格雷（Pravix）不同，它是一种前药，是一种不需要代谢转化的活性药物。
(2R,3S,4R,5R)-2-(Hydroxymethyl)-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol
4,6-Dihydroxy-2-mercaptopyrimidine
1,1,1-Trifluoro-3-iodopropane
(2-Chloroethyl)(methyl)sulfane
(2S,3R,4R,5R)-5-(Acetoxymethyl)tetrahydrofuran-2,3,4-triyl triacetate
(Dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)methyl)phosphonic acid tetrasodium salt
4,6-DICHLORO-2-((3,3,3-TRIFLUOROPROPYL)THIO)PYRIMIDIN-5-AMINE
N-(2-(METHYLTHIO)ETHYL)-2-((3,3,3-TRIFLUOROPROPYL)THIO)-9H-PURIN-6-AMINE
